21 research outputs found
Renal targeting potential of a polymeric drug carrier, poly-L-glutamic acid, in normal and diabetic rats
Singapore's labour force, labour policy and productivity
With increasing global and domestic competition, labour policies haw become one of the most important aspects in governmental economic planning. Though Singapore's workforce is well trained among newly industrialised and developing countries, if must be persistent in upgrading its skills and productivity to meet the challenges aheadACCOUNTANC
Biologically active indole and bisindole alkaloids from Tabernaemontana divaricata
The ethanol extract of the leaves of Tabernaemontana divaricata (double flower variety) provided a total of 23 alkaloids, including the new aspidosperma alkaloids, taberhanine, voafinine, N-methylvoafinine, voafinidine, voalenine and the new bisindole alkaloid, conophyllinine in addition to the previously known, biologically active bisindole, conophylline and its congener, conofoline. The structures of the new alkaloids were established by spectroscopic methods. The preparation and characterization of the corresponding quinones of the biologically active bisindoles are also described in relation to a structure-activity study of these compounds with respect to their action in stimulating insulin expression
Botanical Origin Differentiation of Malaysian Stingless Bee Honey Produced by <i>Heterotrigona itama</i> and <i>Geniotrigona thoracica</i> Using Chemometrics
Stingless bee honey, specifically honeydew honey, is generally valued for its better health benefits than those of most blossom types. However, scientific studies about the differentiation of stingless bee honey based on honeydew and blossom origins are very limited. In this study, 13C NMR spectroscopy was employed to quantify the seven major sugar tautomers in stingless bee honey samples, and the major sugar compositions of both honeydew and blossom types were found not significantly different. However, several physicochemical properties of honeydew honey including moisture content, free acidity, electrical conductivity, ash content, acetic acid, diastase, hydrogen peroxide, and mineral elements levels were significantly higher; while total soluble solid, proline, and hydroxymethylfurfural were significantly lower than blossom honey. Greater antioxidant capacity in honeydew honey was proven with higher total phenolic compounds, ABTS, DPPH, superoxide radical scavenging activities, peroxyl radical inhibition, iron chelation, and ferric reducing power. Using principal component analysis (PCA), two clusters of stingless bee honey from the honeydew and blossom origin were observed. PCA also revealed that the differentiation between honeydew and blossom origin of stingless bee honey is possible with certain physicochemical and antioxidant parameters. The combination of NMR spectroscopy and chemometrics are suggested to be useful to determine the authenticity and botanical origin of stingless bee honey
S-Nitrosylation of Divalent Metal Transporter 1 Enhances Iron Uptake to Mediate Loss of Dopaminergic Neurons and Motoric Deficit
10.1523/JNEUROSCI.3262-17.2018JOURNAL OF NEUROSCIENCE38398364-837
Synthesis, Cytotoxic, Antibacterial and Free Radical Scavenging Activities of Schiff Bases Derived from 1,2,4-Triazole
Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by bcr-abl1, a constitutively active tyrosine kinase fusion gene responsible for an abnormal proliferation of leukemic stem cells (LSCs). Inhibition of BCR-ABL1 kinase activity offers long-term relief to CML patients. However, for a proportion of them, BCR-ABL1 inhibition will become ineffective at treating the disease, and CML will progress to blast crisis (BC) CML with poor prognosis. BC-CML is often associated with excessive phosphorylated eukaryotic translation initiation factor 4E (eIF4E), which renders LSCs capable of proliferating via self-renewal, oblivious to BCR-ABL1 inhibition. In vivo, eIF4E is exclusively phosphorylated on Ser209 by MNK1/2. Consequently, a selective inhibitor of MNK1/2 should reduce the level of phosphorylated eIF4E and re-sensitize LSCs to BCR-ABL1 inhibition, thus hindering the proliferation of BC LSCs. We report herein the structure-activity relationships and pharmacokinetic properties of a selective MNK1/2 inhibitor clinical candidate, ETC-206, which in combination with dasatinib prevents BC-CML LSC self-renewal in vitro and enhances dasatinib antitumor activity in vivo.ASTAR (Agency for Sci., Tech. and Research, S’pore
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia
Chronic myeloid leukemia
(CML) is a myeloproliferative disease
caused by <i>bcr-abl1</i>, a constitutively active tyrosine
kinase fusion gene responsible for an abnormal proliferation of leukemic
stem cells (LSCs). Inhibition of BCR-ABL1 kinase activity offers long-term
relief to CML patients. However, for a proportion of them, BCR-ABL1
inhibition will become ineffective at treating the disease, and CML
will progress to blast crisis (BC) CML with poor prognosis. BC-CML
is often associated with excessive phosphorylated eukaryotic translation
initiation factor 4E (eIF4E), which renders LSCs capable of proliferating
via self-renewal, oblivious to BCR-ABL1 inhibition. <i>In vivo</i>, eIF4E is exclusively phosphorylated on Ser209 by MNK1/2. Consequently,
a selective inhibitor of MNK1/2 should reduce the level of phosphorylated
eIF4E and re-sensitize LSCs to BCR-ABL1 inhibition, thus hindering
the proliferation of BC LSCs. We report herein the structure–activity
relationships and pharmacokinetic properties of a selective MNK1/2
inhibitor clinical candidate, ETC-206, which in combination with dasatinib
prevents BC-CML LSC self-renewal <i>in vitro</i> and enhances
dasatinib antitumor activity <i>in vivo</i>
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia
Chronic myeloid leukemia
(CML) is a myeloproliferative disease
caused by <i>bcr-abl1</i>, a constitutively active tyrosine
kinase fusion gene responsible for an abnormal proliferation of leukemic
stem cells (LSCs). Inhibition of BCR-ABL1 kinase activity offers long-term
relief to CML patients. However, for a proportion of them, BCR-ABL1
inhibition will become ineffective at treating the disease, and CML
will progress to blast crisis (BC) CML with poor prognosis. BC-CML
is often associated with excessive phosphorylated eukaryotic translation
initiation factor 4E (eIF4E), which renders LSCs capable of proliferating
via self-renewal, oblivious to BCR-ABL1 inhibition. <i>In vivo</i>, eIF4E is exclusively phosphorylated on Ser209 by MNK1/2. Consequently,
a selective inhibitor of MNK1/2 should reduce the level of phosphorylated
eIF4E and re-sensitize LSCs to BCR-ABL1 inhibition, thus hindering
the proliferation of BC LSCs. We report herein the structure–activity
relationships and pharmacokinetic properties of a selective MNK1/2
inhibitor clinical candidate, ETC-206, which in combination with dasatinib
prevents BC-CML LSC self-renewal <i>in vitro</i> and enhances
dasatinib antitumor activity <i>in vivo</i>